Lindus Health and Quotient Sciences have announced a strategic partnership to enable enhanced patient recruitment and ...

Title21 Health Solutions, a portfolio company specialising in supporting life science regulatory needs, has joined the Blood ...

Xmoor Pharma has established a strategic collaboration with the Translational Research Office (TRO) and University College ...

Finnish biotechnology company NADMED has announced the launch of the NADMED Award 2026 in the hope of generating new ...

Enterprise Therapeutics has announced the publication of results from its phase 1 study of ETD001, a long-acting inhaled ...

GRI Bio has announced positive topline results from its phase 2a clinical trial evaluating GRI-0621 in idiopathic pulmonary ...

Miranda Dini has announced the launch of GOLD Strategy & Communications, a global healthcare consultancy designed to provide ...

Johnson & Johnson has received European Commission approval for nipocalimab, marketed as IMAAVY, as an add-on therapy for ...

Johnson & Johnson has reported groundbreaking results from the phase 3 MajesTEC-3 study, highlighting the potential of ...

Bayer’s ASSESS study is a randomised, double-blind, placebo-controlled, parallel group phase 2a trial with an extension phase ...

Pharvaris has announced positive topline data from its RAPIDe-3 pivotal phase 3 study, confirming the potential of ...

Steven Pipe, Professor of Pediatrics and Pathology at the University of Michigan, explained: “The five-year HOPE-B results ...